EUCTR2020-003278-37-SE进行中（未招募）1 期
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 - Therapeutics for Inpatients with COVID-19 (TICO)
Regents of the University of Minesota0 个研究点目标入组 1,000 人开始时间: 2020年12月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age = 18 years
- •2.Informed consent by the patient or the patient’s legally-authorized representative (LAR)*
- •3.SARS-CoV-2 infection, documented by a nucleic acid test (NAT) or equivalent testing within 3 days prior to randomization OR documented by NAT or equivalent testing more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the responsible investigator. (For non-NAT tests only those deemed with equivalent specificity to NAT by the protocol team will be allowed. A central list of allowed non-NAT tests will be maintained.)
- •4.Duration of symptoms attributable to COVID-19 = 12 days per the responsible investigator
- •5.Requiring admission for inpatient hospital acute medical care for clinical manifestations of COVID-19, per the responsible investigator, and NOT for purely public health or quarantine purposes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 500
排除标准
- •1.Prior receipt of
- •Any SARS-CoV-2 hIVIG, convalescent plasma from a person who recovered from COVID-19 or
- •SARS-CoV-2 nMAb at any time prior to hospitalization
- •2.Not willing to abstain from participation in other COVID-19 treatment trials until after Day 5 (with thie approval of study leadership enrollment before or on Day 5 is permitted for trials comparing different approaches for implementing SOC interventions that are recommended in a)i))(1)(a)(i)Appendix I
- •3.In the opinion of the responsible investigator, any condition for which, participation would not be in the best interest of the participant or that could limit protocol specified assessments
- •4.Expected inability to participate in study procedures
- •5.Women of child-bearing potential who are not already pregnant at study entry and who are unwilling acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 18 month of the study
- •6.Men who are unwilling acknowledge the strong advice to to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 18 month of the study
- •Prior to the initial futility assessment for an investigational agent, the follwoing two additional exclusions (7 and 8) which define disease severity stratum 2 apply:
- •7.Presence at enrollment of any of the following:
- •b.meningitis
- •c.encephalitis
- •e.myocardial infarction
- •f.myocarditis
- •g.pericarditis
- •h.symptomatic CHF (NYHA class III-IV)
- •i.arterial or deep venous thrombosis or pulmonary embolism
- •8.Current requirement for any of the following:
- •a.invasive mechanical ventilation
- •c.mechanical circulatory support
- •d.vasopressor therapy
- •e.commencement of renal replacement therapy at this admission (i.e. not patients on chronic renal replacement therapy).
- •Additional exclusion citeria according to Protocol amendment for Sweden, No. 2
- •9. Pregnant and nursing women must be excluded.
- •10. AZD7442 are contraindicated in participants who have shown hypersensitivity to the active substance or any of the excipients or to other humanised mAbs.
- •11. For MP0420 there is currently no clinical experience, consequently no specific contraindications have been identified.
- •Exclusions that may be appropriate for an investigational agent studied are referenced in the relevant appendix (H) for the investigational agent. The contraindications for use of components of SOC are outlined in Appendix I and in the PIM
研究者
相似试验
进行中（未招募）
1 期
Therapeutics for Inpatients with COVID-19 (TICO)EUCTR2020-003278-37-PLRegents of the University of Minesota1,000
尚未招募
3 期
Therapeutics for Inpatients with COVID-19 (TICO)CTRI/2021/01/030830ational Institute of Allergy and Infectious Diseases NIAID National Institutes of Health NIH
进行中（未招募）
1 期
Therapeutics for Inpatients with COVID-19 (TICO)Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-003278-37-DKRegents of the University of Minesota1,000
进行中（未招募）
1 期
Therapeutics for Inpatients with COVID-19 (TICO)EUCTR2020-003278-37-GBReagents of the University of Minnesota1,000
进行中（未招募）
1 期
Therapeutics for Inpatients with COVID-19 (TICO)Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-003278-37-ITIVERSITY COLLEGE LONDO2,000